{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:59:17Z","timestamp":1767085157787},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\nBackground\/Aims  The aim of this study was to identify clinical characteristics that distinguish patients who achieve sufficient glycaemic control with basal insulin and oral glucose-lowering medications from those who need treatment intensification.<\/jats:p><jats:p>\nPatients\/Methods  213 out of 1\u2009042 consecutively hospitalized type 2-diabetic patients were treated with basal insulin\/oral agents. After titration to fasting glucose target, in 156 patients (73.2%) continuation of basal insulin treatment was recommended, while in 57 (26.8%), intensification of treatment was necessary. We compared patients\u2019 characteristics and plasma glucose profiles between these groups.<\/jats:p><jats:p>\nResults  Patients needing intensified regimens (basal-bolus regimes, premixed insulin ;GLP-1 receptor agonists) had higher initial HbA1c values (87\u00b117\u2009mmol\/mol [10.1\u00b11.7%] vs. 80\u00b119\u2009mmol\/mol [9.5\u00b11.9%], p=0.028), were more likely to be female (49.1 vs. 25.0%, p=0.0014) and more obese, and required higher basal insulin doses (62\u00b140 vs. 39\u00b127 IU\/d, p&lt;0.0001). In both patient groups, basal insulin reduced fasting plasma glucose into the target range (6.6\u00b11.3 vs. 5.7\u00b10.8\u2009mmol\/l), however, in those needing treatment intensification, post-breakfast plasma glucose remained substantially higher after basal insulin titration (12.6\u00b12.0 vs.9.4\u00b11.6\u2009mmol\/l, p&lt;0.0001). Before hospital discharge, similar plasma glucose profiles were reached in both groups.<\/jats:p><jats:p>\nConclusions  Basal insulin therapy can provide satisfactory glucose control in more than 70% of patients with type 2 diabetes. Long diabetes duration, obesity, insulin resistance and female sex indicate a need for further treatment intensification.<\/jats:p>","DOI":"10.1055\/a-0972-9700","type":"journal-article","created":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T18:54:30Z","timestamp":1565808870000},"page":"663-671","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Predictors of the Need for Further Treatment Escalation in Patients with Type 2 Diabetes on Basal Insulin Therapy \u2013 A Retrospective Observational Study"],"prefix":"10.1055","volume":"127","author":[{"given":"Christina","family":"Buchholz","sequence":"additional","affiliation":[{"name":"Diabetes Center Bad Lauterberg, Bad Lauterberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Kahle-Stephan","sequence":"additional","affiliation":[{"name":"Diabetes Center Bad Lauterberg, Bad Lauterberg, Germany"},{"name":"Diabetes Center Bochum-Hattingen, Medical Department I, St. Josef-Hospital (Ruhr-University Bochum), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juris J.","family":"Meier","sequence":"additional","affiliation":[{"name":"Diabetes Center Bochum-Hattingen, Medical Department I, St. Josef-Hospital (Ruhr-University Bochum), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Nauck","sequence":"additional","affiliation":[{"name":"Diabetes Center Bad Lauterberg, Bad Lauterberg, Germany"},{"name":"Diabetes Center Bochum-Hattingen, Medical Department I, St. Josef-Hospital (Ruhr-University Bochum), Bochum, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2019,8,14]]},"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-0972-9700.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T18:38:30Z","timestamp":1572892710000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-0972-9700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,14]]},"references-count":0,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,11,4]]},"published-print":{"date-parts":[[2019,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-0972-9700","relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,14]]}}}